The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

A study has found a higher risk of suicidal thoughts in users of Novo Nordisk's GLP-1 agonist-based drugs for diabetes and obesity, even though regulators in the US and EU concluded there was no ...

Now, Innovent has said it plans to file for NMPA approval of the drug in diabetes "in the near term." "Mazdutide is the first and fastest-developed [GLP-1/glucagon] dual agonist in the world ...